PUBLISHER: IMARC | PRODUCT CODE: 1541681
PUBLISHER: IMARC | PRODUCT CODE: 1541681
The global E. coli testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.6% during 2024-2032.
Escherichia coli (E. Coli) testing refers to the process of detecting and monitoring the presence of foodborne pathogens. E. Coli bacteria is usually found in contaminated food and water, cheese manufactured from raw milk, undercooked products, unpasteurized milk and raw fruits and vegetables. It can cause various diseases, such as food poisoning, pneumonia and urinary tract infections (UTIs). Some of the clinical testing methods for the detection of E. Coli include enzyme immunoassays (EIA) and polymerase chain reaction (PCR) tests, along with environmental testing methods, such as enzyme-substrate, membrane filtration and multiple tube fermentation (MTF). These techniques aid in obtaining an accurate and quantitative measure of total coliform and bacteria present in the sample.
The increasing prevalence of water-borne diseases, such as diarrhea and hemolytic uremic syndrome (HUS), along with the growing need for clean potable water across the globe, is one of the key factors creating a positive outlook for the market. E. Coli tests can aid in monitoring the quality of surface and drinking water to prevent the spread of illnesses and diseases. Furthermore, the widespread adoption of the enzyme-substrate test as a presence or absence (P/A) test is also driving the market growth. These tests are easy to perform, do not require sophisticated laboratory equipment and use hydrolyzable fluorogenic substrates to detect the presence of various enzymes produced by the bacteria. Additionally, various technological advancements, such as the development of innovative bacterial diagnostic instruments and water testing methods, are contributing to the market growth. Other factors, including increasing health consciousness among the masses, along with extensive research and development (R&D) activities in the field of microbiology, are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global E. coli testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, test type and end user.
Consumables
Instruments
Environmental Test
Membrane Filtration (MF)
Multiple Tube Fermentation (MTF)
Enzyme Substrate Methods
Clinical Test
Polymerase Chain Reaction (PCR) Tests
Enzyme Immunoassays (EIA)
Others
Hospitals and Clinics
Diagnostic Laboratories
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Accugen Laboratories Inc., Alere Inc. (Abbott Laboratories), BD (Becton Dickinson and Company), bioMerieux (INSTITUT MERIEUX), Bio-RAD Laboratories Inc., Enzo Life Sciences Inc. (Enzo Biochem Inc.), Idexx Laboratories Inc., Johnson & Johnson, Meridian Bioscience Inc., Nanologix Inc., Pro-Lab Diagnostics, Qiagen N.V. and Thermo Fisher Scientific Inc.